Orencia has been on the market for rheumatoid arthritis since 2995, with an additional FDA approval for a subcutaneous formulation in 2011 and new indications in psoriatic arthritis and juvenile ...
Biologic response modifier Common adverse effects Rare/serious toxicities Abatacept (Orencia®) Infusion reactions, headaches, upper respiratory tract infections, nasopharyngitis and nausea ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback